We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers


9.90 (2.43%)
Dec 01 2023 - Closed
Delayed by 15 minutes
Company Name Stock Ticker Symbol Market Type
Argen X SE ARGX Euronext Ordinary Share
  Price Change Change Percent Stock Price Last Traded
9.90 2.43% 417.30 11:40:00
Open Price Low Price High Price Close Price Prev Close
410.00 409.60 417.90 417.30 407.40
more quote information »

Recent News

Date Time Source Heading
11/28/202301:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
11/16/202307:40GLOBEargenx Announces European Commission Approval of..
11/01/202302:00GLOBEargenx to Present at Upcoming Investor Conferences
10/31/202302:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
10/24/202301:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
9/21/202301:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
9/15/202301:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
8/30/202301:00GLOBEargenx to Present at Upcoming Investor Conferences
7/27/202301:00GLOBEargenx Reports Half Year 2023 Financial Results and Provides..
7/24/202316:30GLOBEargenx announces closing of global offering
7/20/202301:00GLOBEargenx to Report Half Year 2023 Financial Results and Second..
7/19/202317:58GLOBEargenx announces full exercise of underwriters’ option to..
7/18/202321:30GLOBEargenx raises $1.1 billion in gross proceeds in a global..
7/17/202316:01GLOBEargenx announces launch of proposed global offering
7/17/202301:00GLOBEargenx Reports Positive Topline Data from ADHERE Study of..
6/30/202309:39GLOBEargenx and Zai Lab Announce Approval of VYVGART®..
6/20/202318:12GLOBEargenx Announces U.S. Food and Drug Administration Approval..
6/20/202301:00GLOBEargenx Initiates Second Cohort of Phase 2 ARDA Study of..
5/31/202301:00GLOBEargenx to Present at Upcoming Investor Conferences
5/04/202301:00GLOBEargenx Reports First Quarter 2023 Financial Results and..
5/03/202316:01GLOBEargenx announces results of Annual General Meeting of..
5/02/202301:00GLOBEargenx to Present at BofA Securities 2023 Health Care..
4/27/202301:00GLOBEargenx to Report First Quarter 2023 Financial Results and..
4/18/202301:00GLOBEargenx Demonstrates Commitment to Redefining Treatment Goals..
4/17/202302:00GLOBEargenx and Genmab Enter Partnership to Advance Antibody..
3/17/202316:01GLOBEargenx Announces Annual General Meeting of Shareholders on..
3/15/202309:25GLOBEargenx Announces UK MHRA Approval of VYVGART for the..
3/02/202301:00GLOBEargenx Reports Full Year 2022 Financial Results and Provides..
2/27/202316:01GLOBEargenx Appoints Steve Krognes to Board of Directors
2/27/202301:00GLOBEargenx to Present at Upcoming Investor Conferences
2/23/202301:00GLOBEargenx to Report Full Year 2022 Financial Results and Fourth..
1/27/202301:00GLOBEargenx Receives Notification of PDUFA Date Extension for SC..
1/16/202313:30GLOBEargenx Announces Extraordinary General Meeting of..
1/09/202301:00GLOBEargenx Highlights 2023 Strategic Priorities Across..
1/03/202301:00GLOBEargenx to Present at 41st Annual J.P. Morgan Healthcare..
12/12/202216:01GLOBEargenx Appoints Ana Cespedes to Board of Directors
12/10/202211:30GLOBEargenx to Present Pivotal ADVANCE Trial Data During ASH..

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |